Pacritinib

101 interactions 7 explained in plain English

Also sold as: Vonjo®

About Pacritinib

Pacritinib is used to treat adults with certain types of myelofibrosis (MF; a cancer of the bone marrow in which the bone marrow is replaced by scar tissue and causes decreased blood cell production). Pacritinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal prote… Read the full Pacritinib drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 8, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Oxaliplatin Injection Encorafenib Histrelin Implant Buprenorphine Octreotide Inotuzumab Ozogamicin Injection

100 Major 1 Moderate

All (101) Major (100) Moderate (1)

Major

Pacritinib Clindamycin ANTIROBE Explained Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Pacritinib Amitriptyline Elavil Explained An increased risk of QT interval prolongation Details Pacritinib Sertraline Explained An increased risk of QT interval prolongation Details Pacritinib Buprenorphine Belbuca Explained An increased risk of QT interval prolongation Details Pacritinib Colchicine Colcrys Explained Altered (reduced/increased) CYP3A4/P-gp substrate with NTI exposure, an increased risk of CYP3A4/P-gp substrate with NTI-related a... Details Pacritinib Simvastatin Flolipid Explained Increased BCRP substrate exposure and an increased risk of BCRP substrate-related adverse reactions Details Pacritinib Abemaciclib Verzenio Explained Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Pacritinib Amisulpride Injection Barhemsys An increased risk of QT interval prolongation Details Pacritinib Arsenic Trioxide Trisenox An increased risk of QT interval prolongation Details Pacritinib Aripiprazole Injection Abilify An increased risk of QT interval prolongation Details Pacritinib Arsenic Trioxide Injection Trisenox An increased risk of QT interval prolongation Details Pacritinib Asenapine Transdermal Patch Secuado An increased risk of QT interval prolongation Details Pacritinib Azithromycin AzaSite An increased risk of QT interval prolongation Details Pacritinib Aficamten Reduced aficamten exposure and reduced efficacy of aficamten Details Pacritinib Alfuzosin UroXatral An increased risk of QT interval prolongation Details Pacritinib Anagrelide Agrylin An increased risk of QT interval prolongation Details Pacritinib Axitinib Inlyta Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Pacritinib Bedaquiline Sirturo An increased risk of QT interval prolongation Details Pacritinib Bosutinib Bosulif Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Pacritinib Brigatinib Alunbrig Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Pacritinib Chloroquine Aralen® An increased risk of QT interval prolongation Details Pacritinib Clindamycin Injection ANTIROBE Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Pacritinib Clindamycin Topical C/T/S® Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Pacritinib Clindamycin Vaginal Cleocin Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Pacritinib Cobimetinib Cotellic Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Pacritinib Cyclosporine Injection Atopica Altered (reduced/increased) CYP3A4/P-gp substrate with NTI exposure, an increased risk of CYP3A4/P-gp substrate with NTI-related a... Details Pacritinib Cyclosporine Ophthalmic Cequa Altered (reduced/increased) CYP3A4/P-gp substrate with NTI exposure, an increased risk of CYP3A4/P-gp substrate with NTI-related a... Details Pacritinib Dasatinib Phyrago Reduced CYP3A4 substrate with NTI exposure, reduced efficacy of CYP3A4 substrate with NTI and an increased risk of QT interval pro... Details Pacritinib Degarelix Injection Firmagon An increased risk of QT interval prolongation Details Pacritinib Deutetrabenazine Austedo An increased risk of QT interval prolongation Details Pacritinib Digoxin Cardoxin® Increased digoxin exposure and an increased risk of digoxin-related adverse reactions Details Pacritinib Dihydroergotamine Injection DHE-45® Injection Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Pacritinib Dihydroergotamine Nasal Spray Migranal Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Pacritinib Disopyramide Norpace An increased risk of QT interval prolongation Details Pacritinib Docetaxel Beizray Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Pacritinib Docetaxel Injection Beizray Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Pacritinib Dofetilide Tikosyn Reduced CYP3A4 substrate with NTI exposure, reduced efficacy of CYP3A4 substrate with NTI and an increased risk of QT interval pro... Details Pacritinib Dolasetron Anzemet An increased risk of QT interval prolongation Details Pacritinib Dolasetron Injection Anzemet An increased risk of QT interval prolongation Details Pacritinib Doravirine Pifeltro Reduced doravirine exposure and reduced efficacy of doravirine Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.